Contineum Therapeutics Inc
CTNM12.400USD
+0.010+0.08%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
321.41MMarket Cap
LossP/E TTM
More Details of Contineum Therapeutics Inc Company
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The Company is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
Company Info
Ticker SymbolCTNM
Company nameContineum Therapeutics Inc
IPO dateApr 05, 2024
CEOMr. Carmine Stengone
Number of employees41
Security typeOrdinary Share
Fiscal year-endApr 05
Address3565 General Atomics Court, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code92121
Phone18583335280
Websitehttps://www.contineum-tx.com/
Ticker SymbolCTNM
IPO dateApr 05, 2024
CEOMr. Carmine Stengone
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Carmine Stengone
Mr. Carmine Stengone
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
Mr. John Healy
Mr. John Healy
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Daniel S. Lorrain, Ph.D.
Dr. Daniel S. Lorrain, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Timothy Watkins, M.D.
Dr. Timothy Watkins, M.D.
Chief Medical Officer and Head of Development
Chief Medical Officer and Head of Development
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Ms. Sarah Boyce
Ms. Sarah Boyce
Independent Director
Independent Director
--
--
Ms. Lori M. Lyons-Williams
Ms. Lori M. Lyons-Williams
Independent Director
Independent Director
--
--
Mr. Evert B. (Eef) Schimmelpennink
Mr. Evert B. (Eef) Schimmelpennink
Independent Director
Independent Director
--
--
Ms. Kristina Haeckl
Ms. Kristina Haeckl
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.81%
Johnson & Johnson Innovation-JJDC, Inc.
9.15%
Suvretta Capital Management, LLC
7.95%
Franklin Advisers, Inc.
7.86%
Fidelity Management & Research Company LLC
3.90%
Other
61.33%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
9.81%
Johnson & Johnson Innovation-JJDC, Inc.
9.15%
Suvretta Capital Management, LLC
7.95%
Franklin Advisers, Inc.
7.86%
Fidelity Management & Research Company LLC
3.90%
Other
61.33%
Shareholder Types
Shareholders
Proportion
Venture Capital
24.20%
Hedge Fund
16.57%
Investment Advisor/Hedge Fund
16.16%
Investment Advisor
12.47%
Private Equity
3.23%
Individual Investor
1.61%
Sovereign Wealth Fund
0.78%
Research Firm
0.52%
Other
24.46%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
118
15.39M
71.15%
-1.83M
2025Q1
118
15.85M
82.82%
-1.26M
2024Q4
110
17.13M
89.94%
+2.97M
2024Q3
93
14.98M
78.62%
+2.09M
2024Q2
74
14.21M
74.59%
+7.65M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Johnson & Johnson Innovation-JJDC, Inc.
1.98M
10.34%
--
--
Mar 31, 2025
Suvretta Capital Management, LLC
1.72M
8.99%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.58M
8.23%
+130.62K
+9.04%
Mar 31, 2025
Fidelity Management & Research Company LLC
810.32K
4.23%
+118.44K
+17.12%
Mar 31, 2025
Sectoral Asset Management Inc.
800.79K
4.18%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
803.43K
4.2%
-5.66K
-0.70%
Mar 31, 2025
Perceptive Advisors LLC
1.44M
7.53%
--
--
Mar 31, 2025
HHLR Advisors, Ltd.
669.34K
3.5%
--
--
Mar 31, 2025
Red Tree Management, LLC
638.16K
3.33%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Innovator US Small Cap Managed Floor ETF
0%
iShares Neuroscience and Healthcare ETF
0%
Global X Russell 2000 ETF
0%
Innovator US Small Cap Managed Floor ETF
Proportion0%
iShares Neuroscience and Healthcare ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
